[Neuromidin in mixed vascular and Alzheimer's dementia].

Abstract

The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer's dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of cognitive disorders did not receive the drug. The positive effect was seen in 53,3% of patients of the main group. The worsening was observed in 40% of patients of the comparison group. The positive effect of the drug on spatial and neurodynamic functions was revealed. No serious side-effects of the treatment were found.

• Authors: I V Damulin, D A Stepkina, A B Lokshina
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 111 Issue 2 Pg. 40-3 ( 2011) ISSN: 1997-7298 [Print] Russia (Federation)
• PMID: 21350422 (Publication Type: Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Aminoquinolines
• Cholinesterase Inhibitors
• amiridine

Topics

• Aged
• Aged, 80 and over
• Alzheimer Disease (drug therapy)
• Aminoquinolines (adverse effects, therapeutic use)
• Cholinesterase Inhibitors (adverse effects, therapeutic use)
• Dementia, Vascular (drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Treatment Outcome